Head And Neck Cancer Therapeutics Market Is Estimated To Grow At CAGR Of 8.5 %, 2022-2028 | Latest Industry Coverage By Douglas Insights
November 08, 2022 05:08 ET
|
Douglas Insights
Isle Of Man, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Douglas Insights has made the newest addition to their comparison engine. Head and neck cancer therapeutics market research reports can now be compared...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
October 27, 2022 08:00 ET
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
October 26, 2022 07:30 ET
|
Kura Oncology, Inc.
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors...
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
October 25, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
$10.8 Billion Worldwide Radiation Oncology Industry to 2027 - Featuring Accuray, Canon, Elekta and Hitachi Among Others
September 28, 2022 04:18 ET
|
Research and Markets
Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Heart Failure Therapeutics Market is expected to generate a revenue of USD 15 billion by 2029 Globally at a 3.8% CAGR
September 15, 2022 06:08 ET
|
Exactitude Consultancy
Luton, Bedfordshire, United Kingdom, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has...
Global Oncology Nutrition Markets Report 2022-2026 - Ongoing Research and Development Initiatives Fuel Demand for Oncology Nutrition Products
April 15, 2022 08:13 ET
|
Research and Markets
Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Oncology Nutrition...
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
March 08, 2022 17:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Vaccinex Announces $6.6 Million Private Placement
January 27, 2022 16:15 ET
|
Vaccinex, Inc.
Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) --...
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
December 16, 2021 09:16 ET
|
Kura Oncology, Inc.
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with...